Summary of NEXGEL (NXGLW) Q4 2025 Earnings Call

1Key Financial Results and Metrics

NEXGEL announced the closing of its acquisition of Celularity's degenerative wound segment, expected to triple annual revenue to approximately $35 million and be immediately accretive to profitability.

The company secured $5.5 million in capital from Sequence LifeScience through convertible notes at a $0.60 conversion price, with 50% warrant coverage at a strike price of $0.80.

The transaction structure involved a total payout of $8.3 million, including $5.3 million paid at closing and $2.9 million owed to sales representatives.

2Strategic Updates and Business Highlights

Formation of a new division, BioNX Surgical, focused on advanced biomaterials for various medical applications, including wound care.

The acquisition includes six established regenerative biomaterial products and three additional devices in the pipeline, with expected launches in 2026, 2027, and 2028.

NEXGEL aims to leverage the experienced team from Celularity to enhance its internal capabilities in product development and marketing.

The company is focused on integrating the new assets and driving commercial growth, emphasizing execution and sustained long-term profitability.

3Forward Guidance and Outlook

NEXGEL anticipates achieving EBITDA profitability by Q3 2026, with a projected contribution margin of approximately 52% from the new products.

The company expects a recovery in Q1 2026 following a disappointing Q4 2025, with hopes to return to normal sales levels, particularly in consumer products.

Management expressed confidence in reaching revenue levels similar to those achieved by Celularity in 2024, potentially exceeding $50 million in the next two years.

4Bad News, Challenges, or Points of Concern

Q4 2025 results were below expectations, attributed to underperformance of new products and setbacks in the consumer segment.

The company faces integration challenges and potential restructuring costs, although management indicated that the transition should be relatively seamless due to the existing structure of Celularity's segment.

There is a risk associated with the convertible notes, as failure to maintain profitability could lead to unfavorable outcomes if the notes do not convert.

5Notable Q&A Insights

Management clarified the structure of the acquisition deal and the terms of the convertible note, which has an 18-month maturity and a 10% coupon.

The company will not pay royalties on most acquired products, except for specific projects with Celularity, which have low single-digit royalties.

NEXGEL plans to utilize its new sales force to commercialize both acquired products and its existing medical devices, enhancing overall market reach.

Management acknowledged the need for a strong sales strategy to reinvigorate sales in hospitals where the acquired products are already approved but underutilized.

The potential for stock buybacks was discussed, contingent on achieving solid financial footing and generating cash flow. Overall, NEXGEL's acquisition of Celularity's assets represents a significant strategic shift towards a more diversified medical technology company, with a focus on regenerative medicine and enhanced profitability. However, the company must navigate integration challenges and ensure effective sales execution to realize its growth potential.